GLP-1 Daily: Ozempic & Wegovy News
Brazilian Court Halts Compounded Tirzepatide Program Serving 400
Friday, November 6, 2026 · 5 min
Tirzepatide access for about 400 patients in Urupês, Brazil, is disrupted after a court suspended a municipal compounded-drug program over regulatory compliance questions. The dispute concerns compounded medication, not branded Mounjaro; patients facing treatment interruptions should consult their prescriber about continuity of care.
Listen
Show notes
Tirzepatide access for about 400 patients in Urupês, Brazil, is disrupted after a court suspended a municipal compounded-drug program over regulatory compliance questions. The dispute concerns compounded medication, not branded Mounjaro; patients facing treatment interruptions should consult their prescriber about continuity of care.
In this episode
- Justice suspends Bolsa Mounjaro program in Urupês SP — Juri News
“The Justice of São Paulo determined the suspension of the applications of manipulative tirzepatida offered free of charge by the City Hall of Urupês, in the interior of São Paulo. The decision affects about 400 patients treated by the municipal program known as “Bolsa Mounjaro”…”
- New OAC Research and FDA Guidance Put Medication Apps in the Spotlight - Obesity Action Coalition — Obesity Action Coalition
“The Obesity Action Coalition (OAC) is sharing new research on what patients want from prescription companion apps for obesity medications. The findings come as the U.S. Food and Drug Administration (FDA) has released new guidance on software used with prescription drugs.”
- Lilly at ObesityWeek: weight maintenance, Foundayo, amylin — Dr. Asnat Raziel
“What will Lilly present at ObesityWeek? The American obesity congress runs in Washington from November 14 to 17. Therefore, Lilly is showing several important studies there. The main theme is a question almost every patient asks me. What happens to your weight once the…”